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Objective:To evaluate the impact of the presence ofCNSdisease
at diagnosis in the outcome of AML patients who underwent high-
dose chemotherapy and stem cell transplant. Methods: We per-
formed a retrospective study of all transplants performed for AML
in our institution between 1993 and 2007. Twenty-one patients
(11 males) with CNS disease were identified. Five had unclassified
AML, 2 M1, 2 M2, 9 M4 and 3 MDS. All but one patient had inter-
mediate or poor cytogenetics. Twelve patients were in remission (4
in CR1, 6 in CR2, 2 in greater CR) at the time of transplant. Four
patients had refractory relapse, 4 untreated relapse and one primary
induction failure. All patients were in CNS CR at the time of trans-
plant. Median age was 22.5 years (range 2–66). Three patients re-
ceived autologous graft. The conditioning regimen was
chemotherapy-based in 19 patients [Busulfan (Bu)-Fludarabine
(Flu): 6; Bu-Cyclophosphamide (Cy)-Thiotepa (TEP): 6; Flu-Mel-
phalan (Mel)-TEP: 2; Flu-Mel: 1; Flu-Mel-Mylotarg: 1; Bu-Cy: 1;
Decitabine-Bu-Cy:1; Cy-Etoposide:1]. Two patients received Flu-
Mel with TBI. GVHD prophylaxis was tacrolimus-based in 14/18
allogeneic transplants [with methotrexate (MTX) in 13 or steroids
in one], cyclosporine-based in 2 (one with MTX, one with steroids)
with 2 patients receiving T-cell depleted graft. The donor was
matched related in 9, matched unrelated in 4, mismatched related
in 4 and mismatched unrelated (cord) in 1. Eleven patients received
marrow, 9 PBSC and one cord blood transplant. Patients received
intrathecal chemotherapy monthly  6 months post-transplant as
CNS prophylaxis. Results: Twelve patients died (hemorrhage: 1,
sepsis: 2, acute GVHD: 2, MOF:1, chronic GVHD:1, relapse: 5).
With a median follow-up of 7.5 years, 9 patients are alive, 8 in
CCR, one inCR after CNS relapse and salvage chemotherapy.Con-
clusions:The presence of CNS disease at diagnosis should not pre-
clude the use of stem cell transplantation as treatment for AML.LYMPHOMA/MULTIPLE MYELOMA166
QUANTITATIVE MRD MONITORING IDENTIFIES DISTINCT GVL RE-
SPONSE PATTERNS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
FOR CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS FROM THE GCLLSG
CLL3X TRIAL
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The purpose of this study was to prospectively analyse minimal
residual disease (MRD) kinetics after reduced-intensity allogeneic
stem cell transplantation (allo-SCT) in high-risk chronic lympho-
cytic leukemia (CLL). Subjects were the first 30 consecutive pa-
tients from a prospective disease-specific multicenter clinical trial
by the German CLL Study Group (study patients), and 7 pilot pa-
tients treated identically. All patients had an unfavorable VHmuta-
tional status. Donor lymphocyte infusions (DLI) were administered
preemptively in case of incomplete chimerism and/or stable or in-
creasing MRD, provided that GVHD was absent after complete
withdrawal of immunosuppression.
Results: Using quantitative RQ-PCR and/or flow-based MRD
monitoring (sensitivity.510–4), four distinct patterns of MRD ki-
netics could be identified: (i) patients who achieved durable MRD
negativity without direct evidence of graft-versus-leukemia effects
(GVL; n 5 4); (ii) patients who showed a complete MRD response
to GVL (n5 18); (iii) patients who responded to GVL but failed to
reach complete MRD clearance (n 5 4); and (iv) patients in whom
a GVL effect with subsequent MRD suppression could not be in-
duced (n 5 2). Taking into account 2 non-relapse-related deaths,
study patients had a 54% probability of being alive and MRD-neg-
ative 12 months post transplant. MRD negativity occurring at this
time or later was durable in all cases except one. Three-year non-re-
lapse mortality, event-free, and overall survival of study patients was
11%, 58% and 71%, respectively.Conclusions: Effective GVL ac-tivity can be induced in most patients with high-risk CLL after allo-
SCT according to the design chosen here. GVL occurs essentially
in the context of chronic graft-versus-host disease induced by im-
munosuppression tapering or DLI. However, due to development
of secondaryGVL resistance, in a signficant proportion of cases sus-
tained MRD negativity is not achieved.167
REDUCED INTENSITY VERSUS FULL MYELOABLATIVE STEM CELL
TRANSPLANT FOR ADVANCED CHRONIC LYMPHOCYTIC LEUKEMIA
Peres, E., Levine, J., Kato, K., Krijanovski, O., Khaled, Y., Ferrara, J.,
Yanik, G., Mineishi, S. University of Michigan, Ann Arbor, MI.
Background: Patients with CLL who are refractory to fludara-
bine have a median survival of 12 months. Reduced intensity condi-
tioning (RIC) for stem cell transplant may decrease transplant
related mortality (TRM) compared to full intensity conditioning
(FIC), but long term effectiveness is unclear. We compared out-
comes of 50 patients with advanced CLLwho underwent allogeneic
hematopoietic stem cell transplant (HSCT) at the University of
Michiganwith different intensity conditioning regimens.Methods:
Twenty one patients with CLL received RIC and 29 received FIC
prior to allogeneic HSCT between 1995 and 2005. RIC consisted
of Fludarabine (80–125 mg/m2) Busulfan (6.4 mg/kg IV or 8 mg/
kg oral) and Total lymphoid irradiation of 2–4 Gy. FIC consisted
of either CVB (cyclophosphamide 1800 mg/m2, etoposide 200
mg/m2 and BCNU 450 mg/m2) (n 5 20) or Bu/Cy (busulfan 3.2
mg/kg and cyclophosphamide 60 mg/kg for 2 days) (n 5 9). Graft
versus host disease prophylaxis consisted of tacrolimus and mycofe-
nolate mofetil in the RIC group and tacrolimus andmethotrexate in
the FIC group.Results:Themedian age was 56 years (range 41–61
years) in the RIC group and 50 years (range 26–61 years) in the FIC
group. There was no difference between groups regarding the num-
ber of prior therapies or stem cell source. High risk cytogenetics
were present in 50% (11/21) of the RIC group and 68% (20/29)
(del 17q13 or del 11q22 or complex cytogenetics) in the FIC group.
The donor source consisted of matched unrelated (MUD) 62% (13/
29) in the RIC and 45% (9/20) in the FIC group. RIC recipients
were significantly more likely to be alive at all times post HSCT
(5 y OS RIC 63% versus FIC 18%, p 5 0.006). High TRM was
the primary cause of inferior survival in the FIC recipients who ex-
perienced double the day 100TRM (FIC 27% versus RIC 14%, p5
0.005). The relapse rate was 14% regardless of conditioning regi-
men with the majority of relapses occurring after day 100. Likewise
the incidence of severe GVHD grade II-IV was similar in both
groups (FIC 27% versus RIC 28%). Conclusion: These data sug-
gest that RIC results in significant superior overall survival com-
pared to FIC in patients with CLL despite the higher proportion
of HLA-disparaty in the RIC group. The lower TRM in the RIC
group accounted for the major difference in overall survival.168
UNRELATED CORD BLOOD TRANSPLANTATION IN ADULTS WITH LYM-
PHOID MALIGNANCIES. A EUROCORD/EBMT-LYMPHOMA WORKING
PARTY STUDY
Rodrigues, C.A.1, Sanz, G.2, Brunstein, C.3, Renaud, M.4, Blaise, D.5,
Rio, B.6, Cairo, M.S.7, de Lima, M.8, Sureda, A.9, Wagner, J.3,
Gluckman, E.1, Rocha, V.1 1Eurocord Office, Hopital Saint Louis, Paris,
France; 2Hospital Universitario La Fe, Valencia, Spain; 3University of
Minnesota Medical School, Minneapolis, MN; 4Hopital La Miletrie,
Poitiers, France; 5 Institut Paoli Calmettes, Marseille, France; 6Hotel
Dieu, Paris, France; 7Columbia University, New York, NY; 8MD An-
derson Cancer Center, Houston, TX; 9Hospital Santa Creu i Sant Pau,
Barcelona, Spain.
Umbilical cord blood transplants (UCBT) from unrelated donors
is a feasible option for adults with high-risk acute leukemia. How-
ever, little is known about the outcome of UCBT in patients with
advanced lymphoid malignancies. We evaluated 104 adult patients
(median age, 41 years; range 16–65 years) who received a single
Poster Session I 63(n 5 81) or a double (n 5 23) unrelated UCBT for an advanced
lymphoid malignancy. Sixty-three patients had a non-Hodgkin
lymphoma (18 diffuse large B-cell lymphoma, 10 follicular lym-
phoma, 8 mantle cell lymphoma, 8 peripheral T-cell lymphoma,
14 other T-cell lymphomas, 5 other B-cell lymphomas), 28 had
Hodgkin lymphoma, and 13 had B-cell chronic lymphocytic leuke-
mia (CLL). The majority of patients (85%) had advanced disease
(relapse, refractory disease, partial remission or $3rd complete re-
mission), and 54% had a prior autologous transplant. Based on an-
tigen-level HLA-A and B and allele-level HLA-DRB1 typing, cord
blood units were matched (9%) or mismatched at 1 (26%), 2 (59%)
or 3 (6%) antigens. The median number of cells infused was 2.4 
107 total nucleated cells (TNC)/kg for single transplants and 3.1 
107 TNC/kg for double transplants. Conditioning regimen varied
according to the transplant center, but 62% received a reduced-in-
tensity conditioning (RIC). GVHD prophylaxis was achieved with
cyclosporin and MMF in 48% of cases. Median follow-up time
for survivors was 14 months. The probability of engraftment at
day 60 was 86%, with a median time to engraft of 20 days (3–54).
In a multivariate analysis, a higher cell dose (2.5  107 TNC/kg)
was significantly associated with the neutrophil engraftment (p 5
0.04). Grade II-IV acute graft-versus-host disease (GVHD) was ob-
served in 24% of the patients. Transplant-related mortality (TRM)
was 34% at 6 months. In a multivariate analysis, TRM was signifi-
cantly lower for patients with B-cell malignancies (B-cell non-
Hodgkin lymphomas andCLL) as compared to those withHodgkin
or T-cell lymphomas (21% vs. 49%; p 5 0.005), patients who re-
ceived TBI (25% vs. 49%; p 5 0.04). Disease free survival (DFS)
at 1 year was 40%. In a multivariate analysis, DFS was significantly
better for patients with B-cell malignancies (54% vs. 21%; p 5
0.006) and patients who received TBI (49% vs. 23%; p 5 0.001).
In conclusion, UCBT is a valuable alternative for patients with ad-
vanced non-Hodgkin lymphoma and CLL. B-cell malignancies and
the use of TBI are associated with a significantly better outcome.
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Background: Severe renal failure requiring hemodialysis (HD)
complicates multiple myeloma (MM) in about 3% of cases. Al-
though MM is not a contraindication to chronic dialysis, survival
of MM patients on dialysis is lower than for other conditions such
as diabetes. High dose chemotherapy and autologous stem cell
transplantation (ASCT) is feasible and effective in MM patients
on HD based on small, single center studies. Methods: We con-
ducted a retrospective cohort study of U.S. Medicare primary payer
dialysis patients with multiple myeloma as cause of end stage renal
disease in the U.S. Renal Database System (USRDS) from January
1999 through December 2004 with follow-up through September
2005. Medicare claims for ASCT were based on ICD-9 codes. Lo-
gistic regression was used to assess factors independently associated
with ASCT. Cox time-dependent regression was used to test
whether ASCT was independently associated with survival in this
cohort. Results: There were 3,307 MM patients, of whom 48
(1.5%) underwent ASCT. The mean age of ASCT patients was
60.9 yrs compared to 72.2 yrs in non-ASCT patients (p\ 0.001).
Factors that favored receiving ASCT by logistic regression were:
younger age, higher serum albumin, lower hematocrit and more re-
cent initiation of HD. Factors associated with survival (adjusted
hazard ratios with 95%CI) include ASCT (0.598, 0.352–1.017), Af-
rican-American (0.866, 0.777–0.964), albumin (0.86, 0.804–0.919),
hematocrit, (0.987, 0.979–0.995), age (1.017, 1.012–1.022), and
year of HD initiation, (0.848, 0.822–0.875). The 2-year survival
for ASCT patients was 67.4% and for non-ASCT patients was
24.5%. Conclusions: MM patients on HD rarely undergo
ASCT. The survival of MM patients on HD who do not receive
a transplant is poor. The survival of MM patients on HD who un-
dergo ASCT appears comparable to non-HD patients. Hemodialy-
sis should not be an absolute contraindication to ASCT in MM.170
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HLA-IDENTICAL SIBLING FOR MULTIPLE MYELOMA (MM)
Rotta, M.1,5, Storer, B.1,2, Sahebi, F.3, Shizuru, J.A.4, Benedetto, B.5,
Lange, T.6, Agura, E.D.7, McSweeney, P.A.8, Pulsipher, M.A.9,
Hari, P.10, Maziarz, R.T.11, Chauncey, T.12, Appelbaum, F.R.1,2,
Sorror, M.L.1,2, Bensinger, W.1,2, Sandmaier, B.M.1,2, Storb, R.F.1,2,
Maloney, D.G.1,2 1Fred Hutchinson Cancer Research Center; 2Univer-
sity of Washington; 3City of Hope National Medical Center; 4Stanford
University; 5University of Torino; 6University of Leipzig; 7Baylor Uni-
versity; 8Rocky Mountain Cancer Center; 9University of Utah; 10Medi-
cal College ofWisconsin; 11OregonHealth & Sciences University; 12Puget
Sound VA Medical Center.
Background: Allogeneic hematopoietic cell transplantation
(HCT) following nonmyeloablative conditioning may be used
with lower transplant-related mortality (TRM) in elderly patients
(pts) and/or those with comorbidities. In this approach anti-tumor
activity relies on graft-versus-tumor effects. Here we analyzed out-
comes of nonmyeloablative allografts from HLA-identical sibling
performed by a multicenter consortium in pts with multiple mye-
loma (MM) with a median follow up (FU) of 5 years(y). Patients:
Between March 1998 and February 2007, 133 pts with stage II-III
MM received alloHCT following 2 Gy TBI 1/- fludarabine (48/
133 pts). Median age was 52 (range 31–71) y. Forty-eight and 7
pts (36% and 5%) were older than 55 and 65 y, respectively, and
43% had HCT specific comorbidity scores .1. Median number
of prior treatments was 1(range 1–6) and 44 pts (33%) received 2
or more lines of therapy. One hundred two pts (77%) received their
allografts as consolidation following cytoreductive autografts (con-
ditioning in 97% of pts: melphalan 200 mg/m2). Postgrafting im-
munosuppression was mycophenolate mofetil (MMF) and
cyclosporine (n5 116, 87%) or tacrolimus (n5 17, 13%). At allog-
rafting 86 pts (65%) had chemoresponsive disease with 33 and 53
pts (25% and 40%) in complete (CR) and partial remission (PR), re-
spectively, while 32 and 15 pts (24% and 11%) had chemorefractory
and progressive disease respectively. Results: Median FU for sur-
viving pts was 5(range 0.3–8.5)y. Fifty four(41%) and 12 pts (9%)
had grade 2 to 4 and 3 to 4 acute graft-versus-host-disease
(GVHD); 86 pts (65%) had extensive chronic GVHD. The overall
response rate was 89%, with 73(55%) and 46(34%) pts achieving
CR and PR, respectively.Median time to progressionwas 3.6 y.Me-
dian progression-free survival (PFS) was 2.7 y, and 5-y estimated
PFS was 28%. Nonrelapse mortalities (NRM) at 100 days, 1 and
5 y were 1%, 13% and 24%. Median overall survival (OS) was
reached after 6.2 y, and 5-y estimated OS was 54%. In the subset
of 102 pts who received a tandem auto/allografts, the median time
to progression was 4 y, median PFS was 3 y while median OS has
not been reached. In this group estimated PFS and OS at 3 and 5-
years were 69% and 40%, 80% and 55% respectively.Conclusion:
Nonmyeloablative allografting, in particular as part of a planned
tandem auto/allo HCT protocol, is a treatment option for MM
pts withHLA identical siblings. Future studies are aimed at improv-
ing long-term disease control and reducing GVHD.171
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION HAS CU-
RATIVE POTENTIAL FOR CHEMOREFRACTORY NON-HODGKIN LYM-
PHOMA
Kato, K., Krijanovski, O., Khaled, Y., Peres, E., Reddy, P., Choi, S.,
Kitko, C., Yanik, G., Levine, J., Ferrara, J., Mineishi, S. University of
Michigan, Ann Arbor, MI.
Background: Autologous hematopoietic stem cell transplanta-
tion (auto-HSCT) has been widely used in patients with relapsed
chemosensitive non-Hodgkin lymphoma (NHL), but the prognosis
of patients with chemorefractory NHL remains poor. We com-
pared our experience of allo-HSCT with auto-HSCT for patients
with NHL.Methods: A total of 377 patients with NHL underwent
allo-HSCT (n 5 172, median age: 49 years old, range 18–71) or
auto-HSCT (n 5 205, median age: 56 years old, range 3–71) be-
tween 1996 and 2006 at University of Michigan. Patients who un-
derwent allo-HSCT for relapse after auto-HSCT were excluded.
Chemorefractory disease is defined as stable or progressive disease
